In their study, of the 42 ovarian cancer patients included, 27 (64%) had at least one detectable somatic mutation in their plasma ctDNA (range: 1–3 mutations/sample), and about 50% of the ovarian cancer patients had TP53 mutations. The gene discussed is TP53; the disease is ovarian cancer.